Developmental Cancer Therapeutics In the News
Patients with metastatic kidney cancer who have high rates of distress tend to have poorer overall survival compared to those with low distress, according to a new study by City of Hope researchers.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
City of Hope’s John Zaia, M.D., will lead the development of the phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.
Advanced bladder cancer is particularly difficult to treat. The five-year survival rate for Stage 4 bladder cancer is only about 15 percent. Now, City of Hope researchers have discovered a that a novel drug blocks a key protein that drives the disease.
City of Hope researchers use novel technology to add new functionalities to already potent proteins.
Contemplating Cancer with a Poet and Patient
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.
Fourteen years ago, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., began to travel to underserved countries to perform brain surgeries on disadvantaged children.
From Cuba to Calcutta, across Asia, throughout Europe and North and South America, City of Hope's Yuman Fong, M.D's go-anywhere philosophy has taken him everywhere. Some visits last only a few hours. But each carries a specific purpose.
Neurosurgeon and scientist Rahul Jandial says some symptoms should never be ignored by former cancer patients. More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools.
Ravi Salgia, M.D., Ph.D., recently published in Scientific Reports about a novel and promising link between two NSCLC biomarkers. The study might help oncologists match patients with effective drug interventions against specific forms of NSCLC.
Julie F., 59, of Wisconsin, survived advanced small cell lung cancer after 29 rounds of chemotherapy, five weeks of radiation and experimental immunotherapy. This is her story.
Findings from a new study provide fresh insights into the treatment of women with metastatic breast cancer whose tumors are no longer responding to available treatments.
City of Hope researchers are piloting a new intervention for older patients and their family caregivers to provide “prehabilitation” — a mirror image of the regimen many patients take up after surgery.
George Somlo, M.D., an internationally known breast cancer and hematology researcher at City of Hope, has been named director of pharmaceutical initiatives at City of Hope.
Andrea Bild, Ph.D., serves as professor in the Division of Molecular Pharmacology within the Department of Medical Oncology & Therapeutics Research.
Scientists and researchers will be discussing the advancements in cancer research at the annual European Society for Medical Oncology Congress in Madrid, Spain.
Students spent 10 weeks this summer at the Eugene and Ruth Roberts Summer Student Academy, designed to give hardworking students the opportunity to learn about science by working in a laboratory setting.
A patient who came to City of Hope from his native Beijing, China, through the Center for International Medicine was recently successfully treated. Here is the letter shared by the patient.
A study led by City of Hope neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., offers novel insights on how cancer cells in HER2-positive breast cancer develop the ability to break through the blood-brain barrier and, ultimately, how they can be stopped.